NanJing Pharmaceutical Company Limited (SHSE:600713) entered into Framework Agreement to acquire 55% stake in Suzhou Tianqing Xingwei Pharmaceutical Co., Ltd., a 55% stake in Zhejiang Tianqing Zhongwei Pharmaceutical Co., Ltd., and a 100% of Lianyungang Chia Tai-Tianqing Pharmaceutical Co., Ltd. on December 21, 2022. The provisional estimated price of this transaction is CNY 148 million, and the price should also be The highest transaction price for both parties.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.77 CNY | -2.05% | -3.25% | -1.45% |
1st Jan change | Capi. | |
---|---|---|
-1.45% | 881M | |
+20.53% | 72.45B | |
-4.71% | 23.46B | |
+4.89% | 8.59B | |
+7.11% | 8.35B | |
-23.73% | 7.88B | |
+13.92% | 5.21B | |
-0.59% | 4.11B | |
+7.85% | 4.09B | |
+20.65% | 3.6B |
- Stock Market
- Equities
- 600713 Stock
- News NanJing Pharmaceutical Company Limited
- NanJing Pharmaceutical Company Limited entered into Framework Agreement to acquire 55% stake in Suzhou Tianqing Xingwei Pharmaceutical Co., Ltd., a 55% stake in Zhejiang Tianqing Zhongwei Pharmaceutical Co., Ltd., and a 100% of Lianyungang Chia Tai-Tianqing Pharmaceutical Co., Ltd.